NDAORALTABLET
Approved
Dec 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
5/8 — Partial
UPTRAVI (selexipag) by Johnson & Johnson is prostacyclin receptor agonists [moa]. First approved in 2015.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPTRAVI (selexipag) is an oral prostacyclin receptor agonist approved in December 2015 for pulmonary arterial hypertension (PAH). It works by activating prostacyclin receptors to promote vasodilation and reduce pulmonary vascular resistance. The drug is administered as an oral tablet, offering a convenient dosing option for a chronic, life-threatening condition.
$0.758BPart D
Peak10.9 years to LOEUPTRAVI is a peak-stage product with substantial Medicare spending ($758M in 2023) and a stable patient base, indicating mature commercial operations with established field teams and strong market presence.
Mechanism of Action
Prostacyclin Receptor Agonists
Pharmacologic Class:
Prostacyclin Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension
Started Oct 2020
20 enrolled
Pulmonary HypertensionSchistosomiasis
A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag
Started Oct 2020
372 enrolled
Pulmonary Arterial Hypertension
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
Started May 2017
0Pulmonary Arterial Hypertension
Why This Matters for Your Career
Worked on UPTRAVI at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.